A history of prior bare metal stent restenosis is associated with major adverse cardiac events in subsequent bare metal stenting of de novo coronary lesions

Cardiology

Volumn 116, Issue 3, 2010, Pages 190-193

  Ferguson, Michael A ^a   Needleman, Matthew ^a   Mitchell, Eric S ^b   Carter, Luther I ^c   Bustamante, Alexander I ^a   Love, Kathleen M ^c   Curran, Michael J ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Bare metal stent; Coronary lesion; Major adverse cardiac events; Restenosis

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART DISEASE; HUMAN; IN-STENT RESTENOSIS; MAJOR ADVERSE CARDIAC EVENTS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STENT;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, MILITARY; HUMANS; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; RETROSPECTIVE STUDIES; STENTS; UNITED STATES;

EID: 77955118178     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319472     Document Type: Article

References (18)

1. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-e286.
2. Cutlip D, Chauhan M, Baim D, Ho K, Popma J, Carrozza J, Cohen D, Kuntz R: Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
3. Lowe H, Oesterle S, Khachigian L: Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-193.
4. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden E, Amouyel P, Lablanche J, Bertrand M: Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291-1298.
5. Serruys P, Kutryk M, Ong A: Coronary artery stents. N Engl J Med 2006; 354: 483-495.
6. Spertus J, Nerella R, Kettlekamp R, House J, Marso S, Borkon M, Rumsfeld J: Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. Circulation 2005; 111: 768-773.
7. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neuman F: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-1436.
8. Ellis S, Savage M, Fischman D, Baim D, Leon M, Goldberg S, Hirshfeld J, Cleman M, Teirstein P, Walker C, Bailey S, Buchbinder M, Topol E: Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. Circulation 1992; 86: 1836-1844.
9. Mittal S, Weiss D, Hirshfeld J, Kolansky D, Herrmann H: Comparison of outcome after stenting for De novo versus restenotic narrowings in native coronary arteries. Am J Cardiol 1997; 80: 711-715.
10. Weintraub W, Brown C, Liberman H, Morris D, Douglas J, King S: Effect of restenosis at one previously dilated coronary site on the probability of restenosis at another previously dilated coronary site. Am J Cardiol 1993; 72: 1107-1113. (Pubitemid 24050045)
11. Bresee S, Jacobs A, Garber G, Ruocco N, Mills R, Bergelson B, Ryan T, Faxon D: Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing. Am J Cardiol 1991; 68: 1158-1162.
12. Schuchman M: Debating the risks of drug eluting stents. N Engl J Med 2007; 356: 324-328.
13. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME; BASKET Investigators: Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921-929.
14. Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ: Cost-effectiveness of drugeluting stents including the economic impact of late stent thrombosis. Am J Cardiol 2009; 103: 338-444.
15. Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, Trani C, Rebuzzi AG, Crea F: Association between C-reactive protein and angiographic restenosis after bare metal stents: an update and comprehensive meta-analysis of 2,747 patients. Cardiovasc Revasc Med 2008; 9: 156-165.
16. Hong Y, Jeong M, Lim S, Lee S, Kim K, Sohn I, Park H, Kim J, Kim W, Ahn Y, Cho J, Park J, Kang J: Preinterventional peak monocyte count and in stent hyperplasia after coronary stent implantation in human coronary arteries. Clin Cardiol 2005; 28: 512-518.
17. Love K, Needleman M, Bustamante A, Mitchell E, Carter L, Curran M, Ferguson M: The relation of circulating monocytes to major adverse cardiac events in patients with a history of prior in stent restenosis. Cardiovascular Revascularization Therapy Meeting 2007;Abstract.
18. Horvath C, Welt F, Nedelman M, Rao P, Rogers C: Targeting CCR2 or CD18 inhibits experimental in stent restenosis in primates. Circ Res 2002; 90: 488-494.